UNAIDS
Original Article: bit.ly/1JKHYLu
GENEVA, 24 February 2015—UNAIDS strongly welcomes results from scientific trials presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI), held in Seattle, United States of America. Two studies demonstrate that the antiretroviral medicines tenofovir and emtricitabine when used as pre-exposure prophylaxis (PrEP) are 86% effective in preventing new HIV infections among men who have sex with men.
A third study showed 96% efficacy in preventing new HIV infections when the HIV-negative person in a serodiscordant couple (where one partner is living with HIV and the other is not) had access to PrEP and the HIV-positive partner had access to antiretroviral therapy.
“These new results are a significant breakthrough in advancing efforts to provide effective HIV prevention options to men who have sex with men and to serodiscordant couples,” said Michel Sidibé, Executive Director of UNAIDS. “The results are timely and important and will advance global efforts to end the AIDS epidemic by 2030.”
The PROUD study in the United Kingdom enrolled more than 500 men who have sex with men at higher risk of HIV infection. Half of the participants were given a daily pill of tenofovir and emtricitabine, the other half were deferred for one year before starting PrEP. According to the results presented at CROI, the people taking a daily pill of tenofovir and emtricitabine were 86% less likely to become infected with HIV than the people in the deferred group.
Full text of article available at link below: bit.ly/1JKHYLu
